Home Latest Articles
Latest Articles
  • Yinghui YU, Yang TAN, Guiliang CHEN
    Chinese Journal of Pharmaceuticals. 2024, 55(1): 132-136.
  • Jinlian LI, Yifan YANG, Jinping XIE, Yun WANG, Rong SHAO
    Chinese Journal of Pharmaceuticals. 2024, 55(1): 137-142.
  • Zhixuan SUN, Lingchen GONG, Xin NA, Junxia WANG, Shuzhen CHU
    Chinese Journal of Pharmaceuticals. 2024, 55(1): 143-148.
  • Jia ZHU, Yuqi DING, Hong SHEN, Zhu LIU, Yangdui MAO
    Chinese Journal of Pharmaceuticals. 2024, 55(1): 149-154.
  • Lixiang GONG, Baoxi ZHANG, Yue TAO, Jian ZHOU, Shiying YANG, Yang LYU
    Chinese Journal of Pharmaceuticals. 2023, 54(12): 1687-1693.

    Dynamic vapor sorption(DVS) technology is served as a crucial tool for the examination of pharmaceutical crystal forms and co-crystals. Not only can DVS technology assess moisture sorption performance of an API, but it also probes into phase transition issues, co-crystal screening, quantification of amorphous content at low levels in crystalline materials, as well as the miscellaneous. At present, many countries and regions have included DVS technology into their pharmacopoeias for the exploration of water-solid interactions. However, the Chinese pharmacopoeia has not recorded this technology. This paper provides an overview of the application and advance of DVS technology in the investigation of pharmaceutical crystal forms and co-crystals, as a reference for related research on polymorphism of drugs.

  • Xiangmei LI, Kaidong CHEN, Yong YE, Huafei LUO
    Chinese Journal of Pharmaceuticals. 2023, 54(12): 1694-1703.

    Vaginal drug delivery has attracted great attention due to its advantages such as rich blood supply, large surface area of vagina and avoidance of the hepatic first-pass effect. However, there are still issues such as leakage and discomfort in application of traditional drug dosage forms for vaginal administration. At present, strategies such as bioadhesive materials, thermosensitive materials, pH responsive materials, mucosal penetration techniques and nano technologies have been proposed to improve the retention time, permeability, and release characteristics of drugs in the vagina. Based on the physiological structure and characteristics of the vagina, this review summarizes the delivery strategies and techniques of drug delivery through the vaginal mucosa, hoping to provide a reference for the development of vaginal topical medication and uterine-targeting delivery products.

  • Hongli KONG, Wenzhe WU
    Chinese Journal of Pharmaceuticals. 2023, 54(12): 1704-1712.

    With the increasing number of drug resistant bacteria, antibacterial vaccines, as substitutes for antibiotics, have received wide attention in preventing bacterial infections. Traditional antibacterial vaccines such as the bacillus Calmette-Guérin vaccine, meningococcal polysaccharide vaccine, and pneumococcal conjugate vaccine have been successfully applied to this day, but they also have their own limitations. This situation has driven the development of novel antibacterial vaccines. This review describes the immune characteristics of traditional and new antibacterial vaccines, as well as the clinical marketing of several antibacterial vaccines, in order to provide references for the development of antibacterial vaccines.

  • Gangsheng CHEN, Heng GUO, Fuli ZHANG
    Chinese Journal of Pharmaceuticals. 2023, 54(12): 1713-1717.

    (R)-3-aminobutanol[(R)-1] was a versatile intermediate of several drugs, and it was of great significance to optimize its synthetic process. According to a patent, the final product was (S)-3-aminobutanol instead of the required (R)-product if prepared with (R)-α-phenethylamine[(R)-3] as the chiral auxiliary agent. So, with (S)-3 as the chiral auxiliary agent, compound (R)-3-[[(S)-1-phenylethyl]amino]butan-1-ol[(R)-5] and (S)-5 were prepared by the reductive amination of 4-hydroxy-2-butanone(2), and then (R)-5 and (S)-5 were transformed into the corresponding hydrochlorides. After that, compounds 5 hydrochloride was isolated by recrystallization with a mixed solvent of ethanol and ethyl acetate (volume ratio=3∶1). After alkalization, compound 5 was underwnt the de-benzylation with palladium charcoal and ammonium formate to obtain compound 1 with a total yield of 56.04%(based on 2), a purity of 98.5% and ee of 99%.

  • Ruijie QUAN, Zezhou DING, Fuli ZHANG, Tao ZHANG
    Chinese Journal of Pharmaceuticals. 2023, 54(12): 1718-1723.

    In order to effectively control the quality of naltrexone hydrochloride, seven related substances were synthesized in this study: 17-(1-butenyl)-4,5-epoxy-3,14-dihydroxymorphine-6-one(related substance C), bis-naltrexone(related substance D), 3-cyclopropylmethoxy-17-(cyclopropylmethyl)-4,5-epoxy-14-hydroxymorphine-6-one(related substance E), 17-n-butyl-4,5-epoxy-3,14-dihydroxymorphine-6-one(related substance H), 17-(cyclopropylmethyl)-3-methoxyl-4,5-epoxy-14-hydroxymorphine-6-one(related substance J),17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphin-7-ene-6-one(related substance K), naltrexone nitrogen oxide(related substance L). The related substances K and L were not included in European pharmacopoeia 10.0. The synthetic routes of substances C, D and H had not been reported. The structures of these compounds were confirmed by MS, 1H NMR and 13C NMR.

  • Hongshan YANG, Shu HAN, Wei ZHANG, Youjia HU, Liping XIE
    Chinese Journal of Pharmaceuticals. 2023, 54(12): 1724-1730.

    Palivizumab(Synagis) is a classic drug used to prevent respiratory syncytial virus(RSV). Its application is limited due to its high price. In this study, a Chinese hamster ovary cell line(CHO cells) was engineered to produce palivizumab biosimilars. The key parameters of cell culture were optimized by response surface methodology, and media combinations were screened to increase yield. The results showed that a 16-days cell culture process using AM01-AF02 medium as the basal-feed combination, seeding at 5.0×106 cells per milliliter, and temperature shift from 37 ℃ to 33.0 ℃ on day 7 improved palivizumab production by 69.3% in shake flask and 30.0% in 3 L bioreactor. The purification process at a 3 L bioreactor scale was also studied, which provided a reference for the subsequent process development of palivizumab biosimilars.

News